Travere Therapeutics (TVTX) FDA Announcement summary

Introduction and purpose

• Full FDA approval of FILSPARI (sparsentan) as the only non-immunosuppressive, oral, once-daily treatment proven to significantly slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression, marking a major milestone for patients and the rare kidney disease community.

• The approval expands the indication, removes the proteinuria threshold, and enables earlier treatment, broadening the addressable patient population.

Details of approval or decision

• Full approval is based on long-term confirmatory results from the global, double-blind, randomized Phase III PROTECT Study, demonstrating superior kidney function preservation and durable proteinuria benefit over two years compared to irbesartan.

• The updated label broadens eligibility, removes previous proteinuria thresholds, and allows physician discretion, with inclusion in updated draft KDIGO guidelines recommending earlier intervention and lower proteinuria targets.

• FILSPARI was previously granted accelerated approval in February 2023 based on proteinuria reduction.

• The approval enables expanded commercial communication, educational initiatives, and allows for combination use in simultaneous therapy.

Impact on industry and stakeholders

• The addressable patient population in the US is expected to grow from 30–50,000 to over 70,000, with further growth anticipated due to increased awareness and evolving treatment paradigms.

• FILSPARI is well established in payer plans and formularies, with strong reimbursement metrics and growing demand since launch.

• Travere has established commercial partnerships for global access, including licensing agreements in Asia and conditional marketing authorization in the EU.

• Patient advocacy groups and clinicians highlight the significance of this approval for the rare kidney disease community.